Myxoid Liposarcoma: Treatment Outcomes from Chemotherapy and Radiation Therapy

• Published in: Complexity (New York, N.Y.) N.Y.), 2018, Vol.2018 (2018), p.1-6
• Main Authors: De Amorim Bernstein, Karen, Kim, Jason, Chebib, Ivan, Cote, Gregory M., DeLaney, Thomas F., Goldberg, Saveli, Chowdhry, Varun, Lozano-Calderón, Santiago A.
• Format: Article
• Language: English
• Subjects: Analysis; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical outcomes; Disease control; Gangrene; Liposarcoma; Medical prognosis; Medical research; Medicine, Experimental; Metastases; Metastasis; Multivariate analysis; Myxoid liposarcoma; Oncology; Patients; Radiation therapy; Radiotherapy; Statistical analysis; Stroma; Survival; Treatment outcome
• ISSN: 1076-2787; 1357-714X; 1099-0526; 1369-1643
• DOI: 10.1155/2018/8029157

Introduction. Myxoid liposarcoma (MLS) is a subtype of liposarcoma characterized morphologically by lipomatous differentiation with a myxoid stroma. The purpose of this study was to review clinical and pathological information for patients treated for MLS at our institution to better understand neoadjuvant and adjuvant therapy. Materials and Methods. An institutional database of sarcomas was queried for patients who were treated for MLS at our institution between 1992 and 2013. Survival curves were constructed using Kaplan–Meier analysis, and univariate and multivariate statistics were performed using the Cox-proportional hazards model and using linear regression. Results. A total of 85 patients with myxoid liposarcoma were identified. The mean and median histologic response rate to treatment for patients who received preoperative radiation therapy was 77.6%. Five-year disease-free survival, distant metastasis-free survival, local recurrence-free survival, and overall survival were 78.6% (95% CI: 67.8–86.1), 84.7% (95% CI: 74.5–91.0), 95.6% (95% CI: 86.9–98.6), and 87.5% (95% CI: 77.2–93.3) respectively. On univariate analysis, there was a trend towards higher necrosis or treatment response rates in patients who received concurrent chemotherapy, 84.7% (95% CI: 75.9–93.4) and 69.5% (95% CI: 55.1–83.8), p=0.061. Tumor size was associated with inferior disease-free and overall survival. Hazard ratio for disease-free survival is 1.08 (per cm) (95% CI: 1.01–1.16), p=0.019. Conclusions. Myxoid liposarcoma exhibits histological response to chemotherapy and radiation therapy. Tumor size appears to be greatest predictor of long-term disease control and overall survival. We were not able to show that chemotherapy provides a clinical benefit with regard to local control, disease-free survival, or overall survival. However, it is important to note that the selected usage of chemotherapy in the highest risk patients confounds this analysis. Further investigation is needed to help better determine the optimal use of chemotherapy in this group of patients.